患者性别是否影响免疫检查点抑制剂治疗结局?一项丹麦观察性黑色素瘤研究
该研究利用丹麦转移性黑色素瘤数据库(DAMMED)纳入2013至2021年接受一线免疫检查点抑制剂(ICI)治疗的转移性黑色素瘤(MM)患者1378例,排除辅助治疗及葡萄膜和黏膜组织学亚型。多变量分析校正年龄、体能状态、乳酸脱氢酶水平、BRAF状态、M分期和转移部位数量后,女性在无进展生存(PFS,p=0.014)、总生存(OS,p=0.002)和黑色素瘤特异性生存(MSS,p=0.03)上均显著优于男性。结论认为女性治疗结局优于男性,性别是独立预测变量,但无法判断差异源于生物学还是治疗策略。
要点
- 丹麦全国队列1378例转移性黑色素瘤患者接受一线ICI治疗,女性OS、PFS、MSS均显著优于男性。
- 多变量分析校正年龄、体能状态、LDH、BRAF状态、M分期和转移部位数后,女性仍为独立有利预测因素。
- 全队列5年OS女性47%、男性38%,5年MSS女性50%、男性45%。
核心结论
- 在丹麦全国接受一线ICI治疗的转移性黑色素瘤队列中,女性治疗结局优于男性,性别为独立预测变量,但分析无法判断差异源于生物学还是治疗策略。
研究设计与样本
- 利用丹麦转移性黑色素瘤数据库(DAMMED)识别2013至2021年在丹麦接受一线ICI治疗的MM患者,排除辅助治疗及葡萄膜和黏膜组织学亚型,共纳入1378例,进行单变量和多变量生存分析并描述里程碑生存。
主要发现
- 单变量分析中女性OS显著优于男性(p=0.003)。
- 多变量分析校正年龄、体能状态、乳酸脱氢酶水平、BRAF状态、M分期和转移部位数量后,女性在PFS(p=0.014)、OS(p=0.002)和MSS(p=0.03)上均显著有利。
- 全队列5年OS女性47%、男性38%;5年MSS女性50%、男性45%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 分析无法判断结局差异源于生物学差异还是治疗策略差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The objective of this study was to evaluate whether patient biological sex influences treatment outcomes in patients with metastatic melanoma (MM) undergoing first-line immune checkpoint inhibitor (ICI) therapy. METHODS: The Danish Metastatic Melanoma Database (DAMMED) was employed to identify patients who underwent first-line ICI therapy for MM in Denmark from 2013 to 2021. Excluding adjuvant treatment, uveal and mucosal histological subtypes, the study conducted univariable and multivariable analyses to evaluate the influence of patient sex in survival analyses. Further, landmark survival of this real-world national cohort was described for progression free survival (PFS), overall survival (OS) and melanoma-specific survival (MSS). RESULTS: The analysis encompassed a cohort of 1378 patients with MM. Compared to male sex, females had significantly improved OS (p = 0.003) when tested in univariable testing. Multivariable analyses, controlling for age, performance status, lactate dehydrogenase level, BRAF status, M-stage, and number of metastatic sites revealed significant favourable outcomes associated with female sex irrespective of the considered survival metrics (pPFS = 0.014, pOS = 0.002, and pMSS = 0.03). The observed five-year OS rates of the entire cohort were 47% and 38%, while melanoma-specific survival were 50% and 45% for female and male, respectively. CONCLUSION: In this nationwide cohort of patients with MM undergoing first-line ICI treatment females exhibited superior treatment outcomes compared to males. Sex was identified as an independent predictive variable for treatment outcomes, irrespective of the chosen outcome measures considered. Our analyses are not able to conclude whether the differences in outcome is attributable to differences in biology or to treatment strategy.
引用
- Petersen SK, Hansen CR, Ellebaek E, et al. Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study. Eur J Cancer. 2024. PMID: 38754294. doi:10.1016/j.ejca.2024.114099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。